BSX — Boston Scientific Corporation

Boston Scientific Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $5.442 billion, representing a 7.5% increase year-over-year, with organic revenue growth of 7.0%.
• Adjusted EPS: $0.86, a 15% increase, exceeding guidance of $0.82 to $0.84.
• Adjusted Operating Margin: 28.4%, consistent with expectations and a 70 basis point improvement from Q2 2025.
• Free Cash Flow: $1.290 billion for the quarter, with a full-year expectation of approximately $3.8 billion.
• Debt Leverage Ratio: 2.0x as of June 30, 2026.

2. Strategic Updates and Business Highlights

• Business Growth: Strong performance in Interventional Cardiology, Endoscopy, and Neuromodulation, with Neuromodulation growing 12% and Interventional Cardiology growing 15%.
• Product Launches: FDA clearance for RIVOS in Endoscopy; ongoing trials for TAVR and hypertension treatments expected to launch in 2028.
• Acquisition Plans: Anticipation of closing the Penumbra acquisition in the second half of 2026, expected to enhance the cardiovascular portfolio.
• Restructuring Program: Aimed at achieving approximately $500 million in run-rate savings by 2029 to improve cost efficiency and fund growth initiatives.

3. Forward Guidance and Outlook

• 2026 Guidance: Organic revenue growth revised to 5% to 6%, with adjusted EPS projected at $3.28 to $3.32 (7% to 8% growth).
• Q3 Guidance: Expected organic revenue growth of 3% to 5% and adjusted EPS of $0.80 to $0.82.
• Long-term Outlook: Anticipation of improved growth in 2028, driven by new product launches and market recovery.

4. Bad News, Challenges, or Points of Concern

• Market Slowdown: Significant declines in the WATCHMAN and Electrophysiology (EP) segments, attributed to unexpected competitive pressures and changing referral patterns.
• WATCHMAN Growth: Expected to be flat to low-single digits for the year, with anticipated declines in the second half of 2026.
• EP Market Dynamics: Competitive pressures have led to a decline in market share, and growth is expected to be flat in the second half of 2026.
• Urology Performance: Growth in the Urology segment fell short of expectations, with projections for flat to low-single-digit growth for the year.

5. Notable Q&A Insights

• Guidance Update: CEO Mike Mahoney emphasized that the guidance reduction is primarily due to challenges in the WATCHMAN and EP segments, which were not anticipated.
• Future Growth: Mahoney expressed confidence in the long-term outlook, highlighting that 75% of the business is expected to grow at historical rates, with improvements anticipated in 2027 and 2028.
• WATCHMAN Strategy: The company is focusing on enhancing clinical understanding and expanding physician education to address referral pattern challenges.
• EP Growth Drivers: Upcoming product launches, including FARAWAVE Ultra and entry into the ICE market, are expected to bolster growth in the EP segment starting in 2027.

Overall, while Boston Scientific reported solid Q2 results, the company is navigating significant challenges in key segments, prompting a cautious outlook for the remainder of 2026 and into 2027. However, strategic initiatives and product launches are positioned to support recovery and growth in the longer term.